Publicaciones en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (23)

2024

  1. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023

    Neurologia, Vol. 39, Núm. 2, pp. 196-208

2023

  1. Monitoring response to disease-modifying treatment in multiple sclerosis

    Neurology Perspectives, Vol. 3, Núm. 2

  2. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)

    Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30

  3. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)

    Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60

2022

  1. Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology

    Frontiers in immunology, Vol. 13, pp. 842354

  2. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 59

2021

  1. Risk and outcomes of COVID-19 in patients with multiple sclerosis

    European Journal of Neurology, Vol. 28, Núm. 11, pp. 3712-3721

  2. XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (I)

    Revista de neurologia, Vol. 72, Núm. 11, pp. 397-406

  3. XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (II)

    Revista de neurologia, Vol. 72, Núm. 12, pp. 433-442

2020

  1. Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study

    PLoS ONE, Vol. 15, Núm. 4

  2. Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study

    CNS Drugs, Vol. 34, Núm. 12, pp. 1275-1286

  3. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population

    Journal of Neurology, Vol. 267, Núm. 8, pp. 2362-2371

2019

  1. Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, Núm. 17, pp. 8463-8470

  2. Review of the novelties presented at the 2018 ECTRIMS congress: 11th post-ECTRIMS meeting (II)

    Revista de Neurologia, Vol. 68, Núm. 11, pp. 468-479

  3. Review of the novelties presented at the 2018 ectrims congress: 11th post-ectrims meeting (I)

    Revista de Neurologia, Vol. 68, Núm. 10, pp. 431-441

2017

  1. Multimarker risk stratification approach at multiple sclerosis onset

    Clinical Immunology, Vol. 181, pp. 43-50

  2. Revisión de las novedades del XXXII Congreso ECTRIMS 2016, presentadas en la IX Reunión Post-ECTRIMS (II)

    Revista de Neurologia, Vol. 65, Núm. 2, pp. 75-84

  3. Revisión de las novedades del XXXII congreso ectrims 2016, presentadas en la ix reunión post-ectrims (I)

    Revista de Neurologia, Vol. 65, Núm. 1, pp. 31-40

2016

  1. Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 3, Núm. 3

2013

  1. Consensus document on spasticity in patients with multiple sclerosis

    Revista de Neurologia, Vol. 57, Núm. 8, pp. 359-373